Reuters: Regulatory News: Drug maker Dendreon seeking a buyer -report

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Free Bestselling eBooks Free national bestsellers for your eReader - Fiction, Nonfiction & more! Join 1.5 million book lovers now. Sign-up in under 10 seconds to get the free daily email. From our sponsors

Drug maker Dendreon seeking a buyer -report Oct 25th 2013, 23:57 Fri Oct 25, 2013 7:57pm EDT Oct 25 (Reuters) - Drug maker Dendreon Corp is looking for a suitor after sales for its lead product, prostate cancer drug Provenge, were weaker than expected, according to a Bloomberg report. The Seattle-based company is working with JPMorgan Chase & Co to help it find a buyer, Bloomberg said, citing people familiar with the matter. Dendreon's troubles began in 2011 after the company withdrew its sales forecast for the drug. Questions have also emerged about the veracity of the clinical trials that led to Provenge's approval. The company had said over the years that physician uncertainty about reimbursement and the need for added manufacturing capacity have contributed to slow sales for the drug. Since Provenge's 2010 approval, easier-to-use and more effective prostate cancer treatments have also entered the market.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions